Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges

描述(申请人提供)：糖尿病肾病是糖尿病的一个众所周知的并发症，是慢性肾功能衰竭和终末期肾病(ESRD)的主要原因。护理标准的有限疗效只会在有限程度上推迟向ESRD的进展，再加上我们对这种多方面疾病的不完全了解，突显了揭示新的治疗靶点的重要性。这一为期一天的科学研讨会将于2014年12月9日由纽约科学院在纽约市举行，主题为“糖尿病肾病：药物发现和临床开发挑战”。本次研讨会将融合新技术、目标-疾病关联、基于生理学的见解，并确定新的目标，目标是确定和交付 新的候选药物进入临床，改进现有的治疗方法，并开发新的治疗策略。这次活动将召集大约150名与会者，从学术界、工业界和政府的基础科学家和临床调查人员，到制药战略家和监管专家。这次会议的三个中心目标是：(I)通过演讲、互动辩论和网络活动提供中立的论坛，讨论当前的障碍和新出现的糖尿病肾病靶向治疗的创新方法，如临床前模型和临床试验、信号通路、可用药靶点的确定、毛细血管丢失 (I)促进与晚期疾病状态相关的和过度的抗血管生成活动，并针对肾脏微血管系统；(Ii)通过简短的演讲、海报演示、旅行奖学金、职业指导活动和折扣登记，展示并鼓励职业生涯早期、女性和代表性不足的少数群体研究人员的参与；以及(Iii)促进来自所有部门的国际研究人员之间的合作，以促进将研究转化为更安全、更有效的糖尿病肾脏疾病治疗方法。研讨会的目标与国家糖尿病、消化和肾脏疾病研究所(NIDDK)支持医学研究和研究培训的使命非常一致。NIDDK传播糖尿病和肾脏疾病以科学为基础的信息的目标将通过研讨会的联播和档案作为网络研讨会和开放获取的在线多媒体学院eBriefing实现，并在《纽约科学院年鉴》上发表一份开放获取的、符合第508节的会议报告，该报告将向全球研究和医学界传播研讨会上交换的科学知识和思想。考虑到在不同的研究领域(例如，新的细胞类型、靶点和疗法)和不同的科学方法(例如，动物模型、新的靶标组织)中出现了丰富的新数据，这次研讨会尤其及时。因此，在所有糖尿病肾病利益相关者之间协作检查这一新信息，对于指导该领域的研究进展具有重要价值--特别是关于潜在的新靶点和将新候选药物交付临床的研究。

DESCRIPTION (provided by applicant): Diabetic nephropathy (DN), a well-known complication of diabetes, is the leading cause of chronic renal failure and end-stage renal disease (ESRD). The limited efficacy of the standard of care, which only delays the progression to ESRD to a limited extent, coupled with our incomplete understanding of this multifaceted disease, highlights the importance of unraveling novel therapeutic targets. This 1-day scientific symposium titled, "Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges" will be presented by the New York Academy of Sciences on December 9, 2014, in New York City. This symposium will blend new technologies, target-disease associations, physiology-based insights, and identify novel targets, with the goals of identifying and delivering novel drug candidates into the clinic, improving current treatments, and developing new therapeutic strategies. The event will convene approximately 150 attendees ranging from basic scientists and clinical investigators in academia, industry, and government; to pharmaceutical strategists, and regulatory experts. The three central aims of this conference are to: (i) provide neutral forum through lectures, interactive debates, and networking activities for discussing current hurdles and emerging innovative approaches to DN-targeted therapy, such as preclinical models and clinical trials, signaling pathways, identification of druggable targets, capillary loss and excess anti-angiogenic activity associated with advanced disease states, and targeting the renal microvasculature; (ii) showcase and encourage the participation of early career, female, and underrepresented minority investigators via short talks, poster presentations, travel fellowships, career mentoring activities, and discounted registration; and (iii) foster collaboratin among international investigators from all sectors to promote the translation of research into safer and more efficient diabetic kidney disease therapeutics. The symposium goals align well with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to support medical research and research training. The NIDDK's goal to disseminate science-based information on diabetes and kidney diseases will be met through the symposium's simulcast and archival as a webinar and open-access, online, multimedia Academy eBriefing, and publication of an open-access, Section 508- compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the symposium to the global research and medical communities. This symposium is especially timely given that a wealth of new data has emerged within distinct research areas (e.g., novel cell types, targets, and therapies) and from varied scientific approaches (e.g., animal models, novel target tissues). A collaborative examination of this new information among all diabetic kidney disease stakeholders is therefore of significant value for guiding research forward in the field - particularly with respect to potential novel targets and delivery of novel drug candidates into the clinic.